The coronavirus treatment drugs comprises therapeutics which are used for treatment of the novel coronavirus. There are various drug classes such as corticosteroids, anti-viral, monoclonal antibodies, Kinase inhibitors which can be used for treatment of the coronavirus. The coronavirus is generally treated depending on severity of symptoms such as severe, moderate and mild. The common symptoms of coronavirus are cold, fever, breathlessness, headache, and stomach pain.
Market Dynamics
Key players are focusing on obtaining product approvals in order to strengthen their position in the global coronavirus treatment drugs market. For instance, in June 2020, Glenmark Pharmaceuticals Limited, a pharmaceutical company in India, launched the first orally administered tablet, Fabiflu, for the treatment of patients suffering from mild and moderate symptoms of COVID-19. Fabiflu is available as a 200 mg tablet, has been priced at US$ 1 per tablet. A strip of 34 tablets will cost US$ 47.55 to the patients in India.
Furthermore, key companies are focusing on inorganic strategies such agreements in order to strengthen their position in the global coronavirus treatments drugs market. For instance, in September 2020, Dr Reddy's Laboratories, an Indian pharmaceutical company, announced the launch of Remdesivir under the brand name, Redyx, for the Indian market. The launch of Redyx for treatment for COVID-19 is because of licensing agreement of Dr Reddy Laboratories with Gilead Sciences Inc. which grants Dr Reddy's Laboratories the right to register, manufacture and sell Remdesivir, as a potential treatment for COVID-19 in 127 countries including India.
Key features of the study:
- This report studies the current scenario as well as the future potential of the global coronavirus treatment drugs market. The market for coronavirus treatment drugs is segmented on the basis of drug class, route of administration, distribution channel, and region.
- This report provides in-depth analysis of the global coronavirus treatment drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2020-2027)
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by leading players.
- It profiles leading players in the global coronavirus treatment drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and future plans.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansion and marketing tactics
- The global coronavirus treatment drugs market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
- Stakeholders would greatly benefit in decision making through various strategy matrices used in analyzing the global coronavirus treatment drugs market.
Detailed Segmentation:
- Global Coronavirus Treatment Drugs Market, By Drug Class:
- Corticosteroids
- Anti-viral
- Monoclonal Antibodies
- Kinase Inhibitors
- Others
- Global Coronavirus Treatment Drugs Market, By Route of Administration:
- Global Coronavirus Treatment Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Coronavirus Treatment Drugs Market, By Region:
- North America
- By Drug Class:
- Corticosteroids
- Anti-viral
- Monoclonal Antibodies
- Kinase Inhibitors
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Latin America
- By Drug Class:
- Corticosteroids
- Anti-viral
- Monoclonal Antibodies
- Kinase Inhibitors
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drug Class:
- Corticosteroids
- Anti-viral
- Monoclonal Antibodies
- Kinase Inhibitors
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Drug Class:
- Corticosteroids
- Anti-viral
- Monoclonal Antibodies
- Kinase Inhibitors
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Drug Class:
- Corticosteroids
- Anti-viral
- Monoclonal Antibodies
- Kinase Inhibitors
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug Class:
- Corticosteroids
- Anti-viral
- Monoclonal Antibodies
- Kinase Inhibitors
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Serum Institute of India*
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- Pfizer Inc.
- AstraZeneca plc.
- Bharat Biotech International Limited
- Cadila Healthcare Limited
- Johnson & Johnson
- Moderna
- GlaxoSmithKline plc.
- CanSino Biologics
- Sinovac Biotech
- Novavax, Inc.
- Glenmark Pharmaceuticals Limited
- Dr. Reddy's Laboratories
- Merck & Co., Inc.
“*” marked represents similar segmentation in other categories in the respective section.
